Panntherapi is a biotech company developing Pannexin 1 channel blockers for the treatment of chronic neurological diseases, combining high efficacy and safety, using a unique platform based on human post operative brain tissues. In epilepsy, using ex vivo tissues from drug resistant patients and a rodent model of resistant epilepsy, blocking this activated target allows to drastically reduce the seizures (seizure free in >80% of samples and animals) with no impact on other basal activities.